Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

Source: 
Motley Fool
snippet: 
  • Pfizer, GSK, and Moderna are the leaders in the race to market RSV vaccines.
  • There's a serious unmet need with RSV causing health issues for older adults and children.
  • Pfizer should be a big winner in RSV, but it could have a lower market share than GSK.